key: cord-0825070-kpneo9cv
authors: Sanders, Rogier W; de Jong, Menno D
title: Pandemic moves and countermoves: vaccines and viral variants
date: 2021-03-30
journal: Lancet
DOI: 10.1016/s0140-6736(21)00730-3
sha: 70ac39471dc7304bd4fc20599035202786c8f028
doc_id: 825070
cord_uid: kpneo9cv

nan

In the past few months, the results of several phase 3 studies showing high vaccine efficacy against SARS-CoV-2 and the subsequent rapid regulatory approval and roll-out of several vaccines have ignited much optimism. However, this optimism has been dampened by the emergence of several new virus variants that are more transmissible and less sensitive to vaccine-induced antibodies. 1-6 The extent to which emerging variants affect the efficacy of vaccines appears to vary considerably between vaccines and variants. In The Lancet, Katherine Emary and colleagues 7 show that the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine does retain meaningful efficacy against the B.1.1.7 variant that originated in the UK, 8 although efficacy is probably somewhat reduced compared with that against the original virus strain. The study draws on emerging data from the COV002 trial (NCT04400838), an ongoing phase 2/3 trial assessing the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in the UK. The vaccine was previously reported to have 70·4% efficacy against virologically confirmed symptomatic COVID-19. 9 For the current exploratory analysis, Emary and colleagues exploited the co-circulation of the B. Graver concerns about potential reductions in vaccine efficacy are presented by emerging variants other than B.1.1.7. 1 The Glu484Lys spike mutation, present in the P.1 and B.1.351 strains originating in Brazil and South Africa 10, 11 and several other emerging strains, was not observed in the sequences analysed by Emary and colleagues because it was not circulating widely in the UK during the time of analysis. The Glu484Lys mutation is particularly important because it substantially reduces the neutralisation activity of monoclonal antibodies and serum samples from vaccinees or individuals infected with non-variant viruses. [2] [3] [4] [5] The ChAdOx1 nCoV-19 vaccine had low efficacy in a phase 2 trial in South Africa where B.1.351 variants predominate, 6 which could point to a further loss of vaccine efficacy when variants harbouring Glu484Lys become dominant. Importantly, B.1.1.7 sublineages containing the Glu484Lys mutation have emerged in the UK and elsewhere.

The two desirable effects of COVID-19 vaccines are to prevent severe disease to reduce mortality and alleviate the strain on health systems, and to prevent infection and transmission in order to stop the pandemic. Most of the vaccines in use appear to retain meaningful efficacy in preventing severe disease caused by some of the emerging strains. However, the extent to which prevention of infection and spread is affected receives less attention. In this respect, the low efficacy in preventing asymptomatic infections with the B.1.1.7 variant reported by Emary and colleagues might be concerning, especially in combination with observed higher viral loads in these vaccinees compared with vaccinees infected with other variants. Infection and virus replication in the presence of partial immunity might result in evolution towards escape from vaccine-induced immunity. Reductions in vaccine efficacy rendered by circulating variants of concern might thus facilitate the emergence and spread of progressively resistant variants, especially when delaying or waiving second vaccine doses, with potential consequences for pandemic control. [12] [13] [14] In summary, the early findings reported by Emary and colleagues suggest a meaningful degree of efficacy against the B.1.1.7 variant, which is encouraging. However, additional data are clearly needed to fully appreciate the potential impact of this and other variants of concern on current and future vaccine efficacy, and to provide conclusive evidence that will inform important policy projections and decisions. The COV002 study is ongoing and we eagerly await further data during this anxious time.

RWS declares no competing interests. MDdJ reports personal fees from Janssen Pharmaceuticals, Roche, Cidara Therapeutics, and Vertex, outside the area of work commented on here. RWS and MDdJ's institution, Amsterdam University Medical Centers, has filed a patent application on SARS-CoV-2 antibodies.

SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies

Covid-19: the E484K mutation and the risks it poses

Antibody resistance of SARS-CoV-2 variant B.1.351 and B.1.1.7

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Covid-19 vaccine against the B.1.351 variant

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes

Single dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine

The case against delaying SARS-CoV-2 mRNA vaccine boosting doses